How to buy Exagen stock (XGN)

Exagen is a diagnostics & research business based in the US. Exagen shares (XGN) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $5.02 – an increase of 6.58% over the previous week. Exagen employs 174 staff and has a trailing 12-month revenue of around $56.7 million.

Our top picks for where to buy Exagen stock

Buy Exagen stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Exagen stock price (NASDAQ: XGN)

Use our graph to track the performance of XGN stocks over time.

Exagen shares at a glance

• Key figures

Information last updated 2024-12-19.

Latest market close	$5.02
52-week range	$1.30 - $6.22
50-day moving average more info button	$3.45
200-day moving average more info button	$2.45
Wall St. target price	$6.25
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-0.94

Is it a good time to buy Exagen stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Exagen price performance over time

Historical closes compared with the close of $5.02 from 2024-12-24

1 week (2024-12-18)	-9.06%
1 month (2024-11-26)	27.41%
3 months (2024-09-25)	68.46%
6 months (2024-06-25)	165.61%

1 year (2023-12-22)	195.29%
2 years (2022-12-23)	104.90%
3 years (2021-12-23)	11.02
5 years (2019-12-24)	28

Exagen financials

Revenue TTM	$56.7 million
Gross profit TTM	$21.3 million
Return on assets TTM	-17.41%
Return on equity TTM	-69.97%
Profit margin	-30.56%
Book value	$1.33
Market Capitalization more info button	$97.4 million

TTM: trailing 12 months

Exagen share dividends

We're not expecting Exagen to pay a dividend over the next 12 months.

Exagen share price volatility

Over the last 12 months, Exagen's shares have ranged in value from as little as $1.3 up to $6.22. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Exagen's is 1.346. This would suggest that Exagen's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Exagen overview

Exagen Inc. develops and commercializes various testing products under the AVISE brand in the United States. The company enables healthcare providers to care for patients through the diagnosis, prognosis, and monitoring of autoimmune and autoimmune-related diseases, including systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Its lead testing product is AVISE CTD that enables differential diagnosis for patients presenting with symptoms indicative of various connective tissue diseases (CTDs) and other related diseases with overlapping symptoms. The company offers AVISE Lupus that measures activation of the complement system by quantifying the level of B-cell C4d and erythrocyte bound C4d in the patient's blood; and AVISE APS, which consists of a panel of autoantibody tests that aids in the diagnosis and management of APS. In addition, it provides AVISE Vasculitis AAV, which utilizes a testing panel of individual analytes to provide physicians with results in the assessment and monitoring of anti-neutrophil cytoplasmic antibody associated vasculitis; AVISE SLE Prognostic, a panel of autoantibodies for assessing the potential for complications affecting the kidney, brain, and cardiovascular system; and AVISE Anti-CarP test, which identifies RA patients with severe disease. Further, the company offers AVISE SLE Monitor, a biomarker blood test; AVISE MTX, a patented and validated blood test; and AVISE HCQ, a blood test to monitor levels of hydroxychloroquine.

Frequently asked questions

null
What percentage of Exagen is owned by insiders or institutions?
Currently 29.741% of Exagen shares are held by insiders and 57.215% by institutions. How many people work for Exagen?
Latest data suggests 174 work at Exagen. When does the fiscal year end for Exagen?
Exagen's fiscal year ends in December. Where is Exagen based?
Exagen's address is: 1261 Liberty Way, Vista, CA, United States, 92081 What is Exagen's ISIN number?
Exagen's international securities identification number is: US30068X1037 What is Exagen's CUSIP number?
Exagen's Committee on Uniform Securities Identification Procedures number is: 30068X103